| Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (NCT07594548) | Northwestern University | 2027-09-09 |
| A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, FAST-GO Study (NCT07517211) | Jonsson Comprehensive Cancer Center | 2026-12-01 |
| Individually Tailored, Supervised, Remote Exercise Intervention to Improve Physical Function for Stage I-III Gastroesophageal Cancer Survivors, PRECISE Trial (NCT07439484) | Jonsson Comprehensive Cancer Center | 2026-09-01 |
| Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer (NCT05911243) | University of Washington | 2024-07-22 |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial (NCT06203600) | National Cancer Institute (NCI) | 2024-06-24 |
| Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma (NCT06078709) | Mayo Clinic | 2023-11-20 |
| Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma (NCT05651594) | Roswell Park Cancer Institute | 2023-03-07 |
| mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma (NCT05677490) | Alliance for Clinical Trials in Oncology | 2023-01-31 |
| Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery (NCT04391049) | NRG Oncology | 2021-12-02 |
| Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers (NCT04460937) | National Cancer Institute (NCI) | 2021-04-09 |
| NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer (NCT04615013) | M.D. Anderson Cancer Center | 2020-11-23 |
| A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma (NCT04111172) | Thomas Jefferson University | 2020-11-10 |
| Real-Time Monitoring of Chemotherapy Side-Effects in Patients With Gastrointestinal Cancers, RT-CAMSS Study (NCT04449679) | Thomas Jefferson University | 2020-04-15 |
| Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes (NCT04501913) | City of Hope Medical Center | 2019-12-24 |
| Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma (NCT04097028) | Roswell Park Cancer Institute | 2019-12-20 |
| Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes (NCT04183218) | Mayo Clinic | 2019-09-23 |
| Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer (NCT03801876) | NRG Oncology | 2019-06-26 |
| Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery (NCT03604991) | National Cancer Institute (NCI) | 2019-05-03 |
| Nutritional Supplementation in Reducing Complications in Patients With Locally Advanced Esophageal Cancer Undergoing Chemotherapy, Radiation Therapy, and/or Surgery (NCT04029857) | M.D. Anderson Cancer Center | 2019-03-14 |
| Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma (NCT03784326) | M.D. Anderson Cancer Center | 2019-02-19 |
| Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma (NCT03395847) | M.D. Anderson Cancer Center | 2018-02-09 |